Home · ABOUT US · HISTORY
HISTORY
2019
-
Completed non-clinical test for ciNSC chronic spinal cord injury treatment
(single dose toxicity test, tumorigenicity test, distribution test completed)
2020
-
Registered a patent for ciNSC-derived Small Molecule Compound
-
Patent registration and PCT application for ciNSC, a cell therapy for the treatment of chronic spinal cord injury
-
Investigation of ciNSC direct conversion mechanism of Small Molecules compounds
-
Completed validation of ciNSC amyotrophic lateral sclerosis model
-
Completed validation of ciNSC multiple sclerosis model
2021
-
Establishment of YJ Cerapeutics Inc.
-
Selected as a resident company in Kyung-hee University Campus Town
-
Completed patent technology transfer
-
Establishment of research facility
2022
-
Establishment/certification of corporate research institute
-
Conclusion of YJ102 derivative synthesis research contract
-
Neural progenitor cell therapy CDMO contract signed (Kang Stem Biotech)
-
Venture business certification
-
Overseas patent applications in 4 countries
-
Series A investment attraction
-
Headquarters relocation (Seoul Techno Park)
-
Selected as a start-up growth technology development project by the Ministry of SMEs and Startups ('22~'24)
-
Conclusion of PD model distribution research contract
2023
-
Selected as a Korean Fund for Regenerative Medicine project ('23~'26)
-
Signed a research contract to Quantitative analysis of residual YJ102 in cell solution
-
Signed a research contract to evaluate the effectiveness of ciNSC5
-
Neural progenitor cell treatment technology transfer completed
-
Patent application (use patent)
-
Clinical CRO contract concluded
2024
-
Clinical drug (DP) production completed
before 2018
-
Confirmed validation of ciNSC chronic spinal cord injury animal model
-
Confirmed ciNSC stability
-
Synthesized Small Molecule Compound
-
Grant awarded for Ministry of Health and Welfare project
-
Validated ciNSC cross-differentiation validation